Route of administration other than oral for concomitant me­di­cation [Bioanalytics]

posted by Dr_Dan  – Germany, 2020-02-11 17:20 (1507 d 16:19 ago) – Posting: # 21159
Views: 2,079

Dear qualityassurance
In case of a bioequivalence study, it also depends on whether the concomitant medication was
given obligatory to all subjects or was taken accidentally by one or maybe more subjects. In the first case, the effect for the test and the reference formulation would be the same and you do not need to argue. Otherwise, a detailed risk analysis should be carried out, which describes the estimated PK effects of the concomitant medication on the bioequivalence decision. If only a view subjects are affected a sensitivity analysis could be carried out.
I hope this helps.

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
118 visitors (1 registered, 117 guests [including 6 identified bots]).
Forum time: 09:40 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5